S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Is New IPO Instacart Already Hitting Speed Bumps?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Is New IPO Instacart Already Hitting Speed Bumps?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Is New IPO Instacart Already Hitting Speed Bumps?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Is New IPO Instacart Already Hitting Speed Bumps?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
NASDAQ:ABIO

ARCA biopharma (ABIO) Stock Forecast, Price & News

$2.01
-0.05 (-2.43%)
(As of 09/22/2023 ET)
Compare
Today's Range
$2.01
$2.06
50-Day Range
$2.00
$2.07
52-Week Range
$1.85
$2.70
Volume
10,910 shs
Average Volume
23,740 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ABIO stock logo

About ARCA biopharma (NASDAQ:ABIO) Stock

ARCA biopharma, Inc., a clinical development stage biopharmaceutical company, engages in the development and commercialization of genetically targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. It is also developing Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. The company was founded in 2004 and is headquartered in Westminster, Colorado.

ABIO Price History

ABIO Stock News Headlines

ARCA biopharma, Inc. (NASDAQ:ABIO) Short Interest Down 7.0% in August
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
ABIO - ARCA biopharma, Inc.
"This Could be the Biggest Stock Story of 2023"
A.I. is set to create $7 trillion in new wealth but most investors are buying the wrong stocks. Learn what Wall Street insiders are buying here.
See More Headlines
Receive ABIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABIO Company Calendar

Last Earnings
7/21/2023
Today
9/22/2023
Next Earnings (Estimated)
10/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABIO
Employees
5
Year Founded
N/A

Profitability

Net Income
$-9,930,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.89 per share

Miscellaneous

Free Float
N/A
Market Cap
$28.96 million
Optionable
Not Optionable
Beta
1.30
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Michael R. Bristow M.D. (Age 78)
    Ph.D., Co-Founder, Pres, CEO & Director
    Comp: $358.8k
  • Mr. Thomas A. Keuer (Age 64)
    Chief Operating Officer
    Comp: $360.59k
  • Mr. C. Jeffrey Dekker CPA (Age 58)
    Chief Financial Officer













ABIO Stock - Frequently Asked Questions

How have ABIO shares performed in 2023?

ARCA biopharma's stock was trading at $2.37 on January 1st, 2023. Since then, ABIO stock has decreased by 15.2% and is now trading at $2.01.
View the best growth stocks for 2023 here
.

Are investors shorting ARCA biopharma?

ARCA biopharma saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 242,000 shares, a decline of 7.0% from the August 15th total of 260,300 shares. Based on an average trading volume of 23,000 shares, the short-interest ratio is presently 10.5 days. Approximately 1.7% of the company's stock are short sold.
View ARCA biopharma's Short Interest
.

When is ARCA biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, October 27th 2023.
View our ABIO earnings forecast
.

How were ARCA biopharma's earnings last quarter?

ARCA biopharma, Inc. (NASDAQ:ABIO) announced its earnings results on Friday, July, 21st. The biopharmaceutical company reported ($0.10) EPS for the quarter.

What is Michael R. Bristow's approval rating as ARCA biopharma's CEO?

1 employees have rated ARCA biopharma Chief Executive Officer Michael R. Bristow on Glassdoor.com. Michael R. Bristow has an approval rating of 100% among the company's employees. This puts Michael R. Bristow in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ARCA biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ARCA biopharma investors own include Aurora Cannabis (ACBFF), MannKind (MNKD), Bausch Health Companies (BHC), Biocept (BIOC), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Gilead Sciences (GILD), iBio (IBIO), Nabriva Therapeutics (NBRV) and Synergy Pharmaceuticals (SGYP).

What is ARCA biopharma's stock symbol?

ARCA biopharma trades on the NASDAQ under the ticker symbol "ABIO."

Who are ARCA biopharma's major shareholders?

ARCA biopharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Western Standard LLC (0.00%) and BlackRock Inc. (0.00%). Insiders that own company stock include Christopher David Ozeroff, Fund Lp Funicular and Robert E Conway.
View institutional ownership trends
.

How do I buy shares of ARCA biopharma?

Shares of ABIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ARCA biopharma's stock price today?

One share of ABIO stock can currently be purchased for approximately $2.01.

How much money does ARCA biopharma make?

ARCA biopharma (NASDAQ:ABIO) has a market capitalization of $28.96 million. The biopharmaceutical company earns $-9,930,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis.

How can I contact ARCA biopharma?

ARCA biopharma's mailing address is 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020. The official website for the company is arcabio.com. The biopharmaceutical company can be reached via phone at (720) 940-2100, via email at derek.cole@arcabio.com, or via fax at 720-208-9261.

This page (NASDAQ:ABIO) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -